KYMR — Kymera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815442 ·
Last close
$111.95
Market Cap
$9.21B
52W High
$130.05
52W Low
$53.19
ADV30
701,580
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 65,000,000 | — | -75,607,000 | -61,211,000 | 1,645,444,000 | 124,477,000 | 136,188,000 |
| Mar 2026 | 34,365,000 | — | -84,154,000 | -69,234,000 | 1,669,016,000 | 144,090,000 | 129,379,000 |
| Dec 2025 | 2,870,000 | — | -97,896,000 | -86,981,000 | 1,742,812,000 | 357,011,000 | 163,148,000 |
| Sep 2025 | 2,764,000 | — | -88,666,000 | -82,175,000 | 1,102,044,000 | 112,949,000 | 155,786,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-236,762,000
Investing CF
$-752,492,000
Financing CF
$777,917,000
CapEx
$-1,194,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.24
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,196,406,000
Inventory
—
Receivables
$20,000,000
ST Investments
$566,508,000
EBIT TTM
$-299,271,000
Pretax Income TTM
$-299,601,000
Interest Exp TTM
$330,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$105,000,000
EBITDA
$-339,891,008
Free Cash Flow
$-144,066,752
Enterprise Value
$8,946,568,192
Total Cash
$690,985,024
Total Debt
$78,558,000
Shares Out
82,257,588
Trailing EPS
$-3.26
Book Value
$18.23
ROE
-24.2%
ROA
-15.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 39,211,000 | -345,544,000 | -311,351,000 | 1,742,812,000 | 163,148,000 | 1,579,664,000 | -232,891,000 |
| Dec 2024 | 47,072,000 | -256,710,000 | -223,858,000 | 978,035,000 | 142,416,000 | 835,619,000 | -194,501,000 |
| Dec 2023 | 78,592,000 | -165,530,000 | -146,962,000 | 575,759,000 | 180,788,000 | 394,971,000 | -102,826,000 |
| Dec 2022 | 46,826,000 | -161,256,000 | -154,808,000 | 603,134,000 | 112,983,000 | 490,151,000 | -153,085,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.95
Max Pain — expiry 2027-03-19
max pain strike: $105.00 · spot: $111.95 · call oi: 304 · put oi: 909Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $9.12B | $44.18 | — |
| IBRX | ImmunityBio, Inc. | $8.95B | $8.44 | — |
| PCVX | Vaxcyte, Inc. | $8.36B | $56.21 | — |
| KRYS | Krystal Biotech, Inc. | $10.24B | $345.82 | — |
| RGEN | REPLIGEN CORP | $10.70B | $189.68 | — |
News headlines (Yahoo Finance, 1h cache)
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-02 20:01 · Yahoo
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
2026-09-02 14:59 · Yahoo
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
2026-08-12 17:14 · Yahoo
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
2026-08-06 07:15 · Yahoo
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-28 20:01 · Yahoo
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
2026-07-27 20:01 · Yahoo
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-05 22:01 · Yahoo
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
2026-09-03 15:50 · Yahoo
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
2026-09-01 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.